<code id='E966314D09'></code><style id='E966314D09'></style>

<acronym id='E966314D09'></acronym>

<center id='E966314D09'><center id='E966314D09'><tfoot id='E966314D09'></tfoot></center><abbr id='E966314D09'><dir id='E966314D09'><tfoot id='E966314D09'></tfoot><noframes id='E966314D09'>

<optgroup id='E966314D09'><strike id='E966314D09'><sup id='E966314D09'></sup></strike><code id='E966314D09'></code></optgroup>

<b id='E966314D09'><label id='E966314D09'><select id='E966314D09'><dt id='E966314D09'><span id='E966314D09'></span></dt></select></label></b><u id='E966314D09'></u>

~~<i id='E966314D09'><strike id='E966314D09'><tt id='E966314D09'><pre id='E966314D09'></pre></tt></strike></i>~~

Home» leisure time» comprehensive

comprehensive

comprehensive

author：explore 2025-09-28 21:41:48 Page View：385

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

advertisement

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Gilead acquiring CymaBay and its liver disease drug for $4.3 billion
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

YichuanCao/SipaUSAGileadSciencessaidMondayitwillacquireCymaBayTherapeuticsfor$4.3billion,addinganewt

Anesthesiologist group: stop taking Ozempic before surgery

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Judge denies Trump's request for new trial in E. Jean Carroll case

2:07E.JeanCarrollreactsassheexitstheManhattanFederalCourtfollowingtheverdictinthecivilrapeaccusation

read more